Deciding where to locate clinical trials is a critical and multi-layered investment decision for pharmaceutical companies. Understanding the country selection criteria pharmaceutical companies use is essential for Government policy makers, Regulators and Health authorities to attract clinical inward investments which will generate economic, healthcare and societal value for their local population.
This white paper provides an Investment Criteria Framework with the key factors that pharmaceutical companies assess to decide where to locate clinical development, and makes strategic recommendations for policy makers and policy influencers by country archetype, with actionable initiatives to accelerate clinical trial activity and promote clinical inward investment.
The case for integration and focus
A CRO perspective on accelerating clinical development